Nile Therapeutics buys Capricor
Executive Summary
Cardiovascular-focused Nile Therapeutics Inc. has agreed to acquire privately held Capricor Inc., which is developing cardiac stem cells (CSCs), in a reverse merger. Capricor stockholders will own 90% of the combined company’s shares, and Nile will hold the remainder.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Reverse Acquisition
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice